The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics

Hepatology

Volumn 63, Issue 4, 2016, Pages 1135-1144

  Rein, David B ^a   Borton, Joshua ^a   Liffmann, Danielle K ^a   Wittenborn, John S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHRONIC HEPATITIS C; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; HEALTH CARE COST; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MEDICARE; MIDDLE AGED; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; SIMULATION; AGED; CANCER REGISTRY; COHORT ANALYSIS; DISEASE COURSE; ECONOMICS; FEMALE; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; UNITED STATES; VIROLOGY;

ANTIVIRUS AGENT;

AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MEDICARE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEER PROGRAM; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84960977132     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28430     Document Type: Article

References (33)

1. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160:293-300.
2. Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, Luma HN, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol 2014;60:691-698.
3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.
4. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann Intern Med 2015;163:215-223.
5. Galbraith JW, Donnelly JP, Franco RA, Overton ET, Rodgers JB, Wang HE. National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States. Clin Infect Dis 2014;59:755-764.
6. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013;57:2164-2170.
7. Younossi ZM, Zheng L, Stepanova M, Venkatesan C, Mishra A. Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. BMJ Open 2014;4:e004318.
8. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011;17:531-546.
9. Gordon SC, Hamzeh FM, Pockros PJ, Hoop RS, Buikema AR, Korner EJ, Terrault NA. Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther 2013;38:784-793.
10. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011;43:66-72.
11. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012;54:1259-1271.
12. Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis 2013;56:1382-1393.
13. McEwan P, Ward T, Yuan Y, Kim R, L'Italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 2013;58:54-64.
14. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, Capretta JC, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012;55:1344-1355.
15. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015;162:397-406.
16. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015;61:1860-1869.
17. Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015;162:619-629.
18. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407-419.
19. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis 2015;61:157-168.
20. Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One 2013;8:e58975.
21. Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med 2015;176:65-73.
22. Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol 2013;11:1503-1510.
23. SEER Program. Surveillance, Epidemiology, and End Results (SEER) Program. Medicare Linked Data Set, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released September 2013, based on the July 2013 submission. 2013. Available at: www.seer.cancer.gov. Accessed May 17, 2015.
24. Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, Hamzeh FM. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012;56:1651-1660.
25. Applied Reasearch Cancer Control and Population Sciences. SEER-Medicare: calculation of comorbidity weights. 2013 [cited 2014 Aug 28]. Available at: http://appliedresearch.cancer.gov/seermedicare/program/comorbidity.html. Accessed May 8, 2014.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
27. Bureau of Labor Statistics. CPI detailed report data for June 2014. Table 24. Historical: all items. 2014. Available at: http://www.bls.gov/cpi/cpid1406.pdf. Accessed August 28, 2014.
28. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ 2005;24:465-488.
29. Belotti F, Deb P. TPM: Stata module to estimate two-part cross-sectional models. 2013. Available at: http://ideas.repec.org/c/boc/bocode/s457538.html. Accessed May 17, 2015.
30. Griffiths RI, Gleeson ML, Danese MD, O'Hagan A. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare. Value Health 2012;15:656-663.
31. Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014;161:170-180.
32. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011;45:e17-e24.
33. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138: 513-521, 521.e1-6.